Showing 61-70 of 4088 results for "".
Incorporating Cosmetic Dermatology into Your Medical Practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/incorporating-cosmetic-dermatology-into-your-medical-practice/18763/Cosmetic Dermatology experts Gary D. Monheit, MD, Nancy J. Samolitis, MD, and Joel L. Cohen, MD share tips for adding aesthetic offerings to an established medical dermatology practice or for young physicians opening a new practice. Sitting down with host Neal Bhatia, MD, they all emphasize the impoStevens-Johnson Syndrome: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/stevens-johnson-syndrome-a-case-series/23902/Successful treatment of drug-induced Stevens-Johnson Syndrome using cyclosporine and etanercept.Bryhali, Xepi Launches; Epionce's New Facility
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-bryhali-xepi-launches-epionce-s-new-facility/18213/Bryhali (halobetasol propionate) 0.01% Lotion from Ortho Dermatologics is now available for the topical treatment of plaque psoriasis in adults. Lawrence J. Green, MD a lead investigator on the Phase 3 studies speaks to DermWireTV. Botanical-based skincare company Epionce has a new 18,500 square fooThe Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,The Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.JAK Inhibitors Make the Cut for Alopecia Areata
https://practicaldermatology.com/topics/hair-nails/jak-inhibitors-make-the-cut-for-alopecia-areata/23935/JAK inhibitor approvals increase the opportunity for patients with alopecia areata to experience “life-changing” results.Journal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EPatient-Centered Wound Healing
https://practicaldermatology.com/topics/feature/patient-centered-wound-healing/26645/Patient-Centered Wound HealingDermWireTV: New Data Presented for Atopic Dermatitis and Prurigo Nodularis Candidates at AAD
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-new-data-presented-for-atopic-dermatitis-and-prurigo-nodularis-candidates-at-aad/24127/In this episode of DermWireTV, a phase 3 study finds roflumilast cream is associated with significantly improved atopic dermatitis in children; first-of-its-kind research suggests that eczema treatment lebrikizumab shows efficacy and safety in patients with skin of color; and new data reveals oral JPhase 2 and 3 Trials of JAK Inhibitors For Atopic Dermatitis: A Review
https://practicaldermatology.com/topics/atopic-dermatitis/phase-2-and-3-trials-of-jak-inhibitors-for-atopic-dermatitis-a-review/23265/A number of drugs in development show promise for one of the most challening skin diseases.